| dc.contributor |
Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades |
| dc.contributor.author |
Carrillo, Jorge |
| dc.contributor.author |
Molinos-Albert, Luis M. |
| dc.contributor.author |
Rodríguez de la Concepción, Maria L. |
| dc.contributor.author |
Marfil, Sílvia |
| dc.contributor.author |
García, Elisabet |
| dc.contributor.author |
Derking, Ronald |
| dc.contributor.author |
Sanders, Rogier W. |
| dc.contributor.author |
Clotet, Bonaventura |
| dc.contributor.author |
Blanco, Julià |
| dc.date |
2015 |
| dc.identifier |
Carrillo, J., Molinos-Albert, L. M., De La Concepción, M. L. R., Marfil, S., Garciá, E., Derking, R., et al. (2015). Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals. Plos One, 10(3) |
| dc.identifier |
1932-6203 |
| dc.identifier |
http://hdl.handle.net/10854/3993 |
| dc.identifier |
https://doi.org/10.1371/journal.pone.0120648 |
| dc.identifier.uri |
http://hdl.handle.net/10854/3993 |
| dc.description |
Antibodies with the ability to block the interaction of HIV-1 envelope glycoprotein (Env)
gp120 with CD4, including those overlapping the CD4 binding site (CD4bs antibodies), can
protect from infection by HIV-1, and their elicitation may be an interesting goal for any vaccination
strategy. To identify gp120/CD4 blocking antibodies in plasma samples from HIV-1
infected individuals we have developed a competitive flow cytometry-based functional
assay. In a cohort of treatment-naïve chronically infected patients, we showed that gp120/
CD4 blocking antibodies were frequently elicited (detected in 97% plasma samples) and
correlated with binding to trimeric HIV-1 envelope glycoproteins. However, no correlation
was observed between functional CD4 binding blockade data and titer of CD4bs antibodies
determined by ELISA using resurfaced gp120 proteins. Consistently, plasma samples lacking
CD4bs antibodies were able to block the interaction between gp120 and its receptor, indicating
that antibodies recognizing other epitopes, such as PGT126 and PG16, can also
play the same role. Antibodies blocking CD4 binding increased over time and correlated
positively with the capacity of plasma samples to neutralize the laboratory-adapted NL4.3
and BaL virus isolates, suggesting their potential contribution to the neutralizing workforce
of plasma in vivo. Determining whether this response can be boosted to achieve broadly
neutralizing antibodies may provide valuable information for the design of new strategies
aimed to improve the anti-HIV-1 humoral response and to develop a successful HIV-
1 vaccine. |
| dc.format |
application/pdf |
| dc.language |
eng |
| dc.publisher |
Plos One |
| dc.relation |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120648 |
| dc.rights |
Aquest document està subjecte a aquesta llicència Creative Commons |
| dc.rights |
http://creativecommons.org/licenses/by-nc-nd/3.0/es/ |
| dc.rights |
info:eu-repo/semantics/openAccess |
| dc.subject |
Sida -- Tractament |
| dc.subject |
VIH (Virus) |
| dc.title |
Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals |
| dc.type |
info:eu-repo/semantics/article |
| dc.type |
info:eu-repo/acceptedVersion |
